Log in

NYSE:PRLBProto Labs Stock Price, Forecast & News

+5.05 (+4.13 %)
(As of 08/4/2020 04:00 PM ET)
Today's Range
Now: $127.42
50-Day Range
MA: $116.08
52-Week Range
Now: $127.42
Volume310,013 shs
Average Volume286,724 shs
Market Capitalization$3.39 billion
P/E Ratio58.72
Dividend YieldN/A
Proto Labs, Inc., together with its subsidiaries, operates as an e-commerce driven digital manufacturer of custom parts for prototyping and short-run production worldwide. It utilizes injection molding, computer numerical control machining, three-dimensional (3D) printing, and sheet metal fabrication to manufacture custom parts for developers and engineers who use 3D computer-aided design software to design products across a range of end markets. The company was founded in 1999 and is headquartered in Maple Plain, Minnesota.
Read More
Proto Labs logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.1Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.15 out of 5 stars

Industry, Sector and Symbol

Industry Fabricated structural metal products
Sub-IndustryIndustrial Machinery



Sales & Book Value

Annual Sales$458.73 million
Cash Flow$3.75 per share
Book Value$21.89 per share


Net Income$63.65 million


Market Cap$3.39 billion
Next Earnings Date10/22/2020 (Estimated)
+5.05 (+4.13 %)
(As of 08/4/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PRLB News and Ratings via Email

Sign-up to receive the latest news and ratings for PRLB and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Proto Labs (NYSE:PRLB) Frequently Asked Questions

How has Proto Labs' stock been impacted by COVID-19 (Coronavirus)?

Proto Labs' stock was trading at $78.36 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, PRLB stock has increased by 62.6% and is now trading at $127.42.
View which stocks have been most impacted by Coronavirus

Do Wall Street analysts recommend investors buy shares of Proto Labs?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Proto Labs in the last year. There are currently 5 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Proto Labs

When is Proto Labs' next earnings date?

Proto Labs is scheduled to release its next quarterly earnings announcement on Thursday, October 22nd 2020.
View our earnings forecast for Proto Labs

How were Proto Labs' earnings last quarter?

Proto Labs Inc (NYSE:PRLB) issued its earnings results on Tuesday, July, 28th. The industrial products company reported $0.59 earnings per share for the quarter, topping the Zacks' consensus estimate of $0.36 by $0.23. The industrial products company earned $106.60 million during the quarter, compared to the consensus estimate of $100.46 million. Proto Labs had a return on equity of 10.02% and a net margin of 12.99%. The company's revenue was down 8.0% on a year-over-year basis. During the same period in the previous year, the company posted $0.71 EPS.
View Proto Labs' earnings history

What price target have analysts set for PRLB?

6 Wall Street analysts have issued twelve-month target prices for Proto Labs' shares. Their forecasts range from $69.00 to $145.00. On average, they expect Proto Labs' share price to reach $98.00 in the next year. This suggests that the stock has a possible downside of 23.1%.
View analysts' price targets for Proto Labs

Has Proto Labs been receiving favorable news coverage?

News articles about PRLB stock have trended somewhat positive recently, InfoTrie reports. InfoTrie ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Proto Labs earned a daily sentiment score of 0.8 on InfoTrie's scale. They also gave news articles about the industrial products company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the next several days.
View the latest news about Proto Labs

Are investors shorting Proto Labs?

Proto Labs saw a increase in short interest in the month of June. As of June 30th, there was short interest totaling 4,490,000 shares, an increase of 7.4% from the June 15th total of 4,180,000 shares. Based on an average daily trading volume, of 286,900 shares, the short-interest ratio is presently 15.7 days. Currently, 17.9% of the company's shares are sold short.
View Proto Labs' Current Options Chain

Who are some of Proto Labs' key competitors?

What other stocks do shareholders of Proto Labs own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Proto Labs investors own include Brainstorm Cell Therapeutics (BCLI), Netflix (NFLX), Tesla (TSLA), NVIDIA (NVDA), Starbucks (SBUX), Walt Disney (DIS), Gilead Sciences (GILD), Intel (INTC), Baidu (BIDU) and Alphabet (GOOG).

Who are Proto Labs' key executives?

Proto Labs' management team includes the following people:
  • Ms. Victoria M. Holt, Pres, CEO & Director (Age 61)
  • Mr. John A. Way, CFO & Exec. VP of Devel. (Age 46)
  • Dr. Arthur Richard Baker III, Chief Technology Officer (Age 51)
  • Mr. David M. Fein, Chief Revenue Officer (Age 50)
  • Dan Schumacher, Director of Investor Relations and FP&A

What is Proto Labs' stock symbol?

Proto Labs trades on the New York Stock Exchange (NYSE) under the ticker symbol "PRLB."

Who are Proto Labs' major shareholders?

Proto Labs' stock is owned by many different retail and institutional investors. Top institutional shareholders include Riverbridge Partners LLC (5.73%), Sumitomo Mitsui Trust Holdings Inc. (4.91%), Conestoga Capital Advisors LLC (1.68%), Capital Investment Services of America Inc. (0.47%), Pembroke Management LTD (0.44%) and Envestnet Asset Management Inc. (0.29%). Company insiders that own Proto Labs stock include Arthur R Baker III, John B Goodman, John Way and Robert Bodor.
View institutional ownership trends for Proto Labs

Which institutional investors are selling Proto Labs stock?

PRLB stock was sold by a variety of institutional investors in the last quarter, including Conestoga Capital Advisors LLC, Summit Creek Advisors LLC, SG Americas Securities LLC, Comerica Bank, Pembroke Management LTD, FDx Advisors Inc., Texas Permanent School Fund, and Bender Robert & Associates.
View insider buying and selling activity for Proto Labs

Which institutional investors are buying Proto Labs stock?

PRLB stock was bought by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., Premier Asset Management LLC, Riverbridge Partners LLC, TrimTabs Asset Management LLC, Sciencast Management LP, Strs Ohio, First Trust Advisors LP, and Envestnet Asset Management Inc..
View insider buying and selling activity for Proto Labs

How do I buy shares of Proto Labs?

Shares of PRLB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Proto Labs' stock price today?

One share of PRLB stock can currently be purchased for approximately $127.42.

How big of a company is Proto Labs?

Proto Labs has a market capitalization of $3.39 billion and generates $458.73 million in revenue each year. The industrial products company earns $63.65 million in net income (profit) each year or $2.35 on an earnings per share basis. Proto Labs employs 2,535 workers across the globe.

What is Proto Labs' official website?

The official website for Proto Labs is www.protolabs.com.

How can I contact Proto Labs?

Proto Labs' mailing address is 5540 Pioneer Creek Drive, Maple Plain MN, 55359. The industrial products company can be reached via phone at 763-479-3680 or via email at [email protected]

This page was last updated on 8/5/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.